2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Cannabis Science Outlines Objectives For The New Year; Highlights Include Moving Towards Contracts and Licensing Agreements For Research and Development of New Medicines

Cannabis Science Outlines Objectives For The New Year; Highlights Include Moving Towards Contracts and Licensing Agreements For Research and Development of New Medicines

Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.

Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."

Richard Cowan, Cannabis Science Inc.'s CFO said, "The fact that other groups are willing to enter into licensing agreements with us is further evidence of their respect for Dr. Melamede and his standing in the scientific community Dr. Melamede, is the retired Chairman of the Biology Department at the University of Colorado at Colorado Springs, where he also continues to teach."

On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.

Dr. Robert Melamede, Cannabis Science President and CEO, explained, "These surveys are an example of what we mean when we Cannabis Science Inc. is truly a patient-oriented company. We have their trust because we are patients ourselves. By working with patients both in person and online, we can further develop our knowledge base and add staff and consultants where they are needed."

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements;

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.